1. Efficacy and safety of atezolizumab plus bevacizumab in Korean patients with advanced hepatocellular carcinoma
- Author
-
Jin Won Kim, Il Hwan Kim, Ho Yeong Lim, Jaekyung Cheon, Changhoon Yoo, Jun-Eul Hwang, Dae-Won Lee, Myung Ah Lee, Han Sang Kim, Jung Yong Hong, Hong Jae Chon, and Sang-Bo Oh
- Subjects
medicine.medical_specialty ,Carcinoma, Hepatocellular ,Hepatology ,Bevacizumab ,business.industry ,Liver Neoplasms ,Antibodies, Monoclonal, Humanized ,medicine.disease ,Gastroenterology ,Confidence interval ,Atezolizumab ,Internal medicine ,Hepatocellular carcinoma ,Antineoplastic Combined Chemotherapy Protocols ,Republic of Korea ,medicine ,Humans ,Stage (cooking) ,Neutrophil to lymphocyte ratio ,Adverse effect ,business ,Progressive disease ,Retrospective Studies ,medicine.drug - Abstract
BACKGROUND & AIMS Atezolizumab plus bevacizumab (Ate/Bev) has demonstrated efficacy and safety in patients with advanced hepatocellular carcinoma (HCC) in the phase III trial. Further evaluation is necessary to investigate the safety and efficacy of Ate/Bev in real settings. METHODS This was a multicentre retrospective analysis. Between May 2020 and February 2021, 138 patients received Ate/Bev as first-line treatment for advanced HCC from 11 institutions. We excluded patients with Child-Pugh B or C and BCLC D stage, and the remaining 121 patients were included in this analysis. RESULTS According to RECIST 1.1, the objective response and disease control rates were 24.0% and 76.0%. The median follow-up duration was 5.9 months (95% confidence interval [CI], 5.4-6.4), the median progression-free survival (PFS) was 6.5 months (95% CI, 4.1-9.0), and median overall survival (OS) was not reached (95% CI, not available). The most frequent grade 3-4 adverse event was aspartate aminotransferase elevation (10.7%). In the multivariate analyses, AFP increase (P = .037), baseline neutrophil-to-lymphocyte ratio (NLR) ≥ 5 (P = .023), and best response to stable disease or progressive disease (P = .019) were significantly associated with worse PFS. Macrovascular invasion (P = .048) and baseline NLR ≥5 (P
- Published
- 2021